Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Barbados.
Press releases published on July 10, 2025
Marble Announces its First Vice President of Sales
GlobeNewswire
·
July 10, 2025
Toronto, Ontario, July 10, 2025 (GLOBE NEWSWIRE) -- Marble, the unified health data platform transforming how businesses access, aggregate and analyze electronic health information, today announced the appointment of Brendan Callaghan as Vice President of …
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
GlobeNewswire
·
July 10, 2025
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition …
Avricore Health’s HealthTab™ Platform Expands to North Central London in Groundbreaking NHS Pharmacy-Led Cardiovascular Project
GlobeNewswire
·
July 10, 2025
VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to announce the expansion of its HealthTab™ platform into pharmacies in North Central London—making it the second NHS …
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
GlobeNewswire
·
July 10, 2025
ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as …
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire
·
July 10, 2025
BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced …
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
GlobeNewswire
·
July 10, 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 …
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
GlobeNewswire
·
July 10, 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial …
Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
GlobeNewswire
·
July 10, 2025
- Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors Rome, Italy, 10th July 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and …
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
GlobeNewswire
·
July 10, 2025
Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – …
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
GlobeNewswire
·
July 10, 2025
REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as …
Epitopea renforce ses capacités de recherche et de développement clinique pour accélérer le passage à la clinique
GlobeNewswire
·
July 10, 2025
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 10 juill. 2025 (GLOBE NEWSWIRE) -- Epitopea, société transatlantique d'immunothérapie anticancéreuse développant des immunothérapies à base d'ARN accessibles et prêtes à l'emploi, a annoncé aujourd'hui la formation de …
Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic
GlobeNewswire
·
July 10, 2025
CAMBRIDGE, United Kingdom and MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical …
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
GlobeNewswire
·
July 10, 2025
VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)- …
New Bay Area Lyme Foundation Study Reports That Only One-Third of Early Lyme Patients with On-Going Symptoms Followed up with their Healthcare Providers
GlobeNewswire
·
July 10, 2025
The new research, published in Frontiers in Medicine, points to the need for greater follow-up from medical professionals to address potential treatment failures. PORTOLA VALLEY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading …